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Abstract
Background: Terminalia chebula (Combretaceae) has been widely used in Ayurveda for the treatment of
diabetes. In the present investigation, the chloroform extract of T. chebula seed powder was investigated
for its antidiabetic activity in streptozotocin-induced diabetic rats using short term and long term study
protocols. The efficacy of the extract was also evaluated for protection of renal functions in diabetic rats.
Methods:  The blood glucose lowering activity of the chloroform extract was determined in
streptozotocin-induced (75 mg/kg, i.p.; dissolved in 0.1 M acetate buffer; pH 4.5) diabetic rats, after oral
administration at the doses of 100, 200 and 300 mg/kg in short term study. Blood samples were collected
from the eye retro-orbital plexus of rats before and also at 0.5, 1, 2, 4, 6, 8 and 12 h after drug
administration and the samples were analyzed for blood glucose by using glucose-oxidase/peroxidase
method using a visible spectrophotometer. In long term study, the extract (300 mg/kg) was administered
to streptozotocin-induced diabetic rats, daily for 8 weeks. Blood glucose was measured at weekly intervals
for 4 weeks. Urine samples were collected before the induction of diabetes and at the end of 8 weeks of
treatments and analyzed for urinary protein, albumin and creatinine levels. The data was compared
statistically using one-way ANOVA with post-hoc Dunnet's t-test.
Results: The chloroform extract of T. chebula seeds produced dose-dependent reduction in blood glucose
of diabetic rats and comparable with that of standard drug, glibenclamide in short term study. It also
produced significant reduction in blood glucose in long term study. Significant renoprotective activity is
observed in T. chebula treated rats. The results indicate a prolonged action in reduction of blood glucose
by  T. chebula and is probably mediated through enhanced secretion of insulin from the β-cells of
Langerhans or through extra pancreatic mechanism. The probable mechanism of potent renoprotective
actions of T. chebula has to be evaluated.
Conclusion: The present studies clearly indicated a significant antidiabetic and renoprotective effects
with the chloroform extract of T. chebula and lend support for its traditional usage. Further investigations
on identification of the active principles and their mode of action are needed to unravel the molecular
mechanisms involved in the observed effects.
Published: 07 May 2006
BMC Complementary and Alternative Medicine 2006, 6:17 doi:10.1186/1472-6882-6-17
Received: 05 May 2005
Accepted: 07 May 2006
This article is available from: http://www.biomedcentral.com/1472-6882/6/17
© 2006 Rao and Nammi; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Complementary and Alternative Medicine 2006, 6:17 http://www.biomedcentral.com/1472-6882/6/17
Page 2 of 6
(page number not for citation purposes)
Background
Diabetes mellitus is a debilitating and often life-threaten-
ing disorder with increasing incidence throughout the
world [1]. Diabetic complications arise partly from glyco-
sylation damage to structural and functional proteins and
reflect chronic failure to maintain blood glucose homeos-
tasis. Other complications such as diabetic nephropathy,
diabetic retinopathy, diabetic neuropathy and diabetic
cardiomyopathy prevail as a result of hyperglycemia. A
scientific investigation of traditional herbal remedies for
diabetes may provide valuable leads for the development
of alternative drugs and strategies. Alternatives are clearly
needed for better management of diabetes because of high
cost and poor availability of current therapies for many
rural populations, particularly in developing countries.
Diabetic nephropathy is one of the microvascular compli-
cations of diabetes. The pathophysiology involves an
interaction between metabolic and hemodynamic factors.
Metabolic factors include advanced glycation, increased
formation of polyols and activation of protein kinase-C.
Hemodynamic factors include systemic hypertension, int-
raglomerular hypertension and the role of vasoactive hor-
mones, such as anglotensin II. Clinical course progresses
from microalbuminuria to overt proteinuria and then to
renal failure [2].
The field of herbal medicines research has been gaining
significant importance in the last few decades and the
demand to use natural products in the treatment of diabe-
tes is increasing worldwide. The available literature shows
that there are more than 400 plant species showing antid-
iabetic activity [3,4]. Although some of these plants have
great reputation in Ayurveda, the indigenous Indian sys-
tem of medicine, many remain to be scientifically estab-
lished [5].
The dried ripe fruit of Terminalia chebula Retz. (Combreta-
ceae), is used extensively in Ayurveda and is widely dis-
tributed throughout India, Burma and Sri Lanka. It is
commonly known as black myroblans in English and has
traditionally been used in the treatment of asthma, sore
throat, vomiting, hiccough, diarrhoea, bleeding piles,
gout and heart and bladder diseases [6]. A herbal formu-
lation containing T. chebula under the name 'TRIPHALA'
is a very popular traditional medicine for the treatment of
chronic disorders including diabetes [7,8]. It is reported to
have antioxidant and free radical scavenging activities [9].
It has shown effectiveness against cancer cells [10] and
helicobacter pylori [11]. It is also useful as anticaries agent
[12] in dermal wound healing [13], improving gastroin-
testinal motility [14] and anaphylactic shock [15]. The
methanolic extract of T. chebula has been shown to exhibit
antidiabetic activity in rats [16]. Although the fruits are
known for their antidiabetic properties, the whole powder
of dried ripe fruits is also being widely used for the control
of diabetes. So far, little is known on the medicinal values
of T. chebula seeds. In the present study, the chloroform
extract of the seeds of T. chebula was tested for its antidia-
betic activity using short term and long term study proto-
cols after oral administration in streptozotocin-induced
diabetic rats. Moreover, the extract was also tested for its
renoprotective effects upon long term study in diabetic
rats.
Methods
Plant material and extraction
Fresh seeds of T. chebula were purchased from the local
traders and shade dried to obtain a completely dried prod-
uct. An authenticated voucher specimen (No. SP-26) of
the plant has been preserved in our Department for future
reference. The dried seeds were then milled to fine powder
(3 kg) and extracted with chloroform in Soxhlet's appara-
tus for 24 h and the extract was evaporated to dryness
under vacuum and dried in vacuum desiccator (270.8 g).
Chemicals used
Glibenclamide was a generous gift sample from Sun Phar-
maceuticals Limited, Baroda, India and streptozotocin
was purchased from Sigma-Aldrich, St. Louis, USA. Glu-
cose, albumin, creatinine and protein assay kits were
obtained from the Diagnostic Division of Dr. Reddy's Lab-
oratories, Hyderabad, India. All other chemicals used
were of analytical grade.
Animal experiments
Male Sprague Dawley rats procured from Mahaveer Enter-
prises, Hyderabad, India were used in the studies. All the
animal experiments were conducted according to the pro-
tocols approved by the Institutional Animal Ethics Com-
mittee (Reg. No. 516/01/A/CPCSEA). Animals were
divided into 8 groups of five each and were fed with stand-
ard diet (Ratan Brothers, Hyderabad) and water ad libitum.
They were kept in clean and dry cages and maintained in
well-ventilated animal house with 12 h light-12 h dark
cycle. Rats were rendered diabetic by injecting a freshly
prepared streptozotocin (75 mg/kg, i.p.; dissolved in 0.1
M acetate buffer; pH 4.5) [17] after a base-line blood glu-
cose estimation was done. After two weeks, animals with
blood glucose levels above 450 mg/dl were selected for
the study.
Short term studies
Groups I, II and III were given orally, the T. chebula extract
in the form of suspension in 1% sodium CMC at doses of
100, 200 and 300 mg/kg respectively. Group IV was served
as control and received equivalent volumes of vehicle.
Group V received glibenclamide at a dose of 0.04 mg/kg
and served as standard. Animals were fasted for 16 h prior
to drug administration allowing access only to water.
Blood samples were collected from retro-orbital plexus ofBMC Complementary and Alternative Medicine 2006, 6:17 http://www.biomedcentral.com/1472-6882/6/17
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each rat before and also at 0.5, 1, 2, 4, 6, 8 and 12 h after
treatments. The samples were analyzed for blood glucose
content by using glucose-oxidase/peroxidase method
[18,19] with optical density measured at 505 nm using a
visible spectrophotometer.
Long term studies
For long term evaluation, groups of rats were given daily
treatments for 8 weeks. Animals in group VI were given
orally, the T. chebula extract (suspended in 1% sodium
CMC) at a dose of 300 mg/kg. Group VII served as control
while group VIII received glibenclamide at a dose of 0.04
mg/kg. Blood samples were collected from the overnight
fasted animals and fasting blood glucose levels were
measured before and also at weekly intervals for 4 weeks.
For urinary collection, rats were housed in metabolic
cages at the start (pre-diabetic condition) and at the end
(8th week) of the experiment. The 24 h urinary samples
were collected from all the animals after have been accli-
matized in metabolic cages for 3 days. The measurements
of urinary protein [20], albumin [21] and creatinine [22]
were done using commercial diagnostic kits following
manufacturer's instructions.
Statistical analysis
Data are expressed as mean ± standard error of mean. Sta-
tistical analysis was done using one-way analysis of vari-
ance (ANOVA) and post-hoc comparisons were carried
out using Dunnet's t-test. P values <0.05 were considered
as significant.
Results
Short term studies
The chloroform extract of T. chebula seeds produced sig-
nificant antidiabetic effect with various doses in strepto-
zotocin-induced diabetic rats in acute study. It produced a
dose-dependent reduction in blood glucose with doses of
100, 200 and 300 mg/kg compared to control group
(Table 1). Glibenclamide (0.04 mg/kg) also produced a
significant reduction in blood glucose compared to con-
trol group. T. chebula produced a maximum reduction of
blood glucose of 20.85% (p < 0.01), 28.45% (p < 0.001)
and 42.20% (p < 0.001) at 4 h with doses of 100, 200 and
300 mg/kg respectively, where as glibenclamide (0.04 mg/
kg) produced a maximum reduction of 50.44% (4 h, p <
0.001) compared to control group.
Long term studies
Long term administration of T. chebula (300 mg/kg) to
streptozotocin-induced diabetic rats for four weeks pro-
duced significant reduction in blood glucose. The reduc-
tion was significant after treatment for one week in both
the extract and glibenclamide treated groups and contin-
ued to increase up to four weeks (Table 2). At the end of
4th week, T. chebula extract produced significant blood glu-
cose reduction of 53.09% (p < 0.01). On the other hand,
glibenclamide produced significant blood glucose reduc-
tion of 60.10% (p < 0.01).
The urinary excretion profile of protein, albumin and cre-
atinine is shown in Figure 1. Streptozotocin-induced dia-
betic rats displayed a significant (p < 0.001) increase in
urinary protein, albumin and creatinine after 8 weeks as
compared to their pre-diabetic state levels. However, rats
Effect of T.chebula on urinary excretion of protein (A), albu- min (B) and creatinine (C) in streptozotocin-induced diabetic  rats Figure 1
Effect of T.chebula on urinary excretion of protein 
(A), albumin (B) and creatinine (C) in streptozo-
tocin-induced diabetic rats. Each bar indicates the mean 
± SEM of 5 animals in each group. Urine samples were col-
lected before the induction of diabetes (0 week) and after 8 
weeks of daily treatments either with vehicle (control), T. 
chebula (300 mg/kg) or glibenclamide (0.04 mg/kg) in strepto-
zotocin-induced diabetic rats. Significant difference from the 
corresponding pre-diabetic value: **p < 0.001.
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treated with T. chebula (300 mg/kg) or glibenclamide
(0.04 mg/kg) for 8 weeks did not produce any change in
urinary protein, albumin or creatinine compared to their
corresponding pre-diabetic values.
Discussion
Diabetes mellitus is possibly the World's largest growing
metabolic disorder, and as the knowledge on the hetero-
geneity of this disorder is advanced, the need for more
appropriate therapy increases [23]. The enormous costs of
modern medicines indicate that alternative strategies are
required for better management of diabetes. Traditional
plant medicines are used throughout the world for a range
of diabetic complications. The study of such medicines
might offer a natural key to unlock a diabetologist's phar-
macy for the future.
For the study of antidiabetic agents, streptozotocin-
induced hyperglycemia in rodents is considered to be a
good preliminary screening model and is widely used
[24]. Streptozotocin, N- [methylnitrocarbamoyl]-D-glu-
cosamine is a potent methylating agent for DNA and acts
as nitric oxide donor in pancreatic β-cells and thus β-cells
are more sensitive to damage by nitric oxide and free rad-
ical scavenging enzymes [25]. T. chebula is widely used as
a traditional medicine by diabetic patients in India.
Although the fruits are known for their antidiabetic prop-
erties, the whole powder of dried ripe fruits is also being
widely used for the control of diabetes. So far, little is
known on the medicinal values of T. chebula seeds. In the
present study the chloroform extract of the seeds of T.
chebula was evaluated and the data also confirmed the tra-
ditional indications. Our data on the seed extract of T.
chebula indicated a potent action in short term study and
a prolonged duration of antidiabetic action in long term
study and this could be due to multiple sites of action pos-
sessed by the active principles of T. chebula.
The study also revealed that T. chebula is more effectively
inhibited the incidence of diabetic nephropathy. Diabetic
nephropathy is mainly associated with excess urinary
albumin excretion, abnormal renal function as repre-
sented by an abnormality in serum creatinine. The com-
mon progression from microalbuminuria to overt
nephropathy has led many to consider microalbuminuria
to define early or incipient nephropathy. Renal disease is
suspected to be secondary to diabetes in the clinical set-
ting of long-standing diabetes. Clinically, diabetic neph-
ropathy is characterized by a progressive increase in
proteinuria and decline in GFR, hypertension, and a high
risk of cardiovascular morbidity and mortality. The patho-
physiology involves glucose that binds irreversibly to pro-
Table 2: Percent blood glucose reduction produced by T. chebula after chronic administration in streptozotocin-induced diabetic rats
Group (n = 5) Dose (mg/kg) Percent blood glucose reduction
123 4  ( W e e k s )
Control ---- -19.72 ± 8.05 -14.35 ± 4.92 -7.06 ± 4.28 -12.48 ± 7.55
T. chebula 300 38.75 ± 8.09* 45.20 ± 11.64* 48.10 ± 5.25* 53.09 ± 3.14*
Glibenclamide 0.04 48.09 ± 10.90* 55.75 ± 8.03* 58.88 ± 5.08* 60.10 ± 2.70*
Values are represented as mean ± S.E.M.; n = number of animals per group
Significant difference from control group at identical times, *P < 0.01
Table 1: Percent blood glucose reduction produced by T.chebula after oral administration in streptozotocin-induced diabetic rats.
Group (n = 
5)
Dose (mg/
kg)
Percent blood glucose reduction
0 . 5 12468 1 2  ( h r s )
Control --- -5.65 ± 1.80 -8.10 ± 3.29 -1.35 ± 6.62 -12.09 ± 4.48 -7.25 ± 4.90 -4.19 ± 2.08 -7.03 ± 8.15
T.chebula 100 -2.18 ± 3.95 8.45 ± 9.27 17.82 ± 5.38* 20.85 ± 5.29* 19.94 ± 6.18* 10.98 ± 8.54 8.36 ± 3.18
T.chebula 200 1.28 ± 4.72 20.28 ± 6.29* 31.98 ± 
8.24**
28.45 ± 
6.20**
26.55 ± 
2.70**
18.25 ± 5.21* 12.86 ± 8.20*
T.chebula 300 -1.18 ± 4.25 25.88 ± 
10.05**
38.92 ± 
7.18**
42.20 ± 
4.65**
33.09 ± 
8.05**
27.85 ± 
4.78**
22.90 ± 
7.55**
Glibenclamide 0.04 24.92 ± 8.20* 32.37 ± 
4.60**
38.72 ± 
10.22**
50.44 ± 
8.40**
46.56 ± 
4.60**
23.11 ± 6.75* 10.26 ± 11.03
Values are represented as mean ± SEM.; n = number of animals per group
Significant difference from control group at identical times, *P < 0.01; **P < 0.001BMC Complementary and Alternative Medicine 2006, 6:17 http://www.biomedcentral.com/1472-6882/6/17
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teins in the kidney and circulation to form advanced
glycosylation end products (AGEs). AGEs can form com-
plex crosslinks over years of hyperglycemia and can con-
tribute to renal damage by stimulation of growth and
fibrotic factors via receptors for AGEs. Increased glomeru-
lar capillary pressure occurs early in diabetes and is asso-
ciated with hyperfiltration at the glomerulus. The
glomerular mesangium expands, initially by cell prolifer-
ation and then by cell hypertrophy. Increased mesangial
stretch and pressure can stimulate this expansion, as can
high glucose levels. Mediators of proliferation and expan-
sion include platelet-derived growth factor and transform-
ing growth factor-β (TGF-β). TGF-β are particularly
important in the mediation of expansion and later fibrosis
via  the stimulation of collagen and fibronectin. Angi-
otensin-II (AT-II) also contributes to the progression of
diabetic nephropathy. AT-II preferentially constricts the
efferent arteriole in the glomerulus, leading to higher
glomerular capillary pressure. In addition to its hemody-
namic effects, AT-II also stimulates renal growth and
fibrosis through AT-II type 1 receptors, which secondarily
upregulate TGF-β and other growth factors. The extract
due to its significant hypoglycemic activity may have
inhibited the formation of advanced glycosylation end
products. However the extract may also have effect on the
above stated other mechanisms.
Further work on fractionation, purification, identification
of active principle(s) and detailed mechanistic evaluation
responsible for these activities are obviously required on
the seeds of T. chebula. The possible mechanisms behind
the hypoglycemic activity and the inhibition of incidence
of diabetic nephropathy are yet to be studied.
Conclusion
In conclusion, the present studies indicated a significant
antidiabetic and renoprotective effects with the chloro-
form extract of Terminalia chebula and support its tradi-
tional usage in the control of diabetes and its
complications. Further investigations to identify the active
principle(s) are obviously needed together with a detailed
evaluation on the mechanisms involved in the observed
activities.
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